The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression. The FDA has granted accelerated approval to ...

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma. The objective response rate (ORR) for belzutifan in patients with ...